Drugs / CMMAd
CMMAd
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02292628 | Oct 2013 → Sep 2017 | — | Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CMMAd | “This is a clinical trial phase I/II, double blind, randomized to compare in two groups of patients to evaluate the safety and efficacy of the autologous mesenchymal stem cells...” NCT02292628 ↗ |
| Known as | autologous mesenchymal stem cells from the adipose tissue | “This is a clinical trial phase I/II, double blind, randomized to compare in two groups of patients to evaluate the safety and efficacy of the autologous mesenchymal stem cells...” NCT02292628 ↗ |
| Modality | Cell therapy | “autologous mesenchymal stem cells” NCT02292628 ↗ |
| Route | Other | “unique intralesional infusion” NCT02292628 ↗ |